Call Action Canada for Sexual Health and Rights to obtain information regarding existing abortion providers in your area: 1-888-642-2725.

To find lists of all service providers in your area, search the Provincial/Territorial College of Physicians and Surgeons:

College of Physicians and Surgeons of Alberta

British Colombia
College of Physicians and Surgeons of British Columbia

College of Physicians and Surgeons of Manitob

New Brunswick
College of Physicians and Surgeons of New Brunswick

Newfoundland and labrador
College of Physicians and Surgeons of Newfoundland and Labrador 

northwest territories
Northwest Territories Health and Social Service

Nova scotia
College of Physicians and Surgeons of Nova Scoti

General Practice Physicians of Nunavut

Ontario College of Physicians and Surgeons

prince edward island
College of Physicians and Surgeons of Prince Edward Islan

College of Physicians and Surgeons of Saskatchewa

Collège des médecins du Québe

Yukon Medical Council


Sample Letter


[Name of health service provider]


Dear ________,

As a supporter of Canada’s universal health care program, [I’m/we are] writing to express concern regarding the roll-out of the gold-standard drug “Mifegymiso” used for medical abortions.  

[If applicable, about your organization.]

As you may know, people in Canada experience many challenges in accessing abortion services. The majority of clinics are located in urban areas within 150km from the US border. Only 1/6 hospitals provide abortion services. This means that many women have to travel long distance (sometimes out of country) at their own expense to access timely care. No medically necessary procedure should be so difficult to access.

Mifegymiso has the potential to overcome many of these barriers; yet, the drug was approved with unnecessary restrictions, including the requirement that only physicians dispense the drug. No other drug, including highly controlled substances like methadone, have this requirement. Mifegymiso will also only be available until 7 weeks gestation, compared to 10 weeks like it is in the US. Cost will present another significant barrier. Mifegymiso is expected to be rolled-out at a cost of $300/regimen and provinces and territories have yet to include the drug in their insurance plans.

Together, these restrictions will severely impact access to a procedure which all people in Canada have a right to.

We request your support in addressing barriers in access to safe abortion services by:

  • Becoming trained to dispense Mifegymiso and encouraging colleagues to do the same as part of a package of sexual and reproductive health services; 
  • Engaging professional bodies towards Health Canada’s easing of restrictions associated with Mifegymiso; and
  • Encouraging government officials to include Mifegymiso in health insurance plans, while ensuring free access to the drug for uninsured women and trans folk.

[I/We] welcome the opportunity to meet with you to discuss these recommendations. [I/We] can be reached at [email + phone number].

Thank you in advance and [I/We] look forward to hearing back from you soon,